Importance Dementia affects 10% of those 65 years or older and 35% of those 90 years or
older, often with profound cognitive, behavioral, and functional consequences. As the baby …

Plant-derived multitarget compounds may represent a promising therapeutic strategy for
multifactorial diseases, such as Alzheimer's disease (AD). Artemisinin and its derivatives …

Objectives Decision-analytic models assessing the value of emerging Alzheimer's disease
(AD) treatments are challenged by limited evidence on short-term trial outcomes and …

Background The approval of lecanemab, an anti-amyloid therapy for Alzheimer's disease
(AD), necessitates addressing healthcare preparedness for disease-modifying treatment …

Objectives Reimbursement decisions for new Alzheimer's disease (AD) treatments are
informed by economic evaluations. An open-source model with intuitive structure for model …

In the ever-evolving landscape of Alzheimer's treatment, lecanemab (Leqembi) has
emerged as a promising drug. Unlike conventional therapies that merely alleviate …

Alzheimer's disease, prevalent in individuals aged 60 and above, constitutes most dementia
cases and significantly impairs memory and cognitive functions. With global Alzheimer's …

Objectives Nursing home (NH) administrator perceptions regarding the utility of Alzheimer's
disease (AD) disease-modifying medications in NHs are important because many short and …

Alzheimer's disease (AD) is a neurodegenerative disorder that accounts for 60%–70% of
patients with dementia, and it is estimated that over one million Canadians will be living with …

Lecanemab and donanemab are monoclonal antibody therapies that remove amyloid-beta
from the brain. They are the first therapies that alter a fundamental mechanism, amyloid-beta …